{
  "@context": "aku-v2",
  "@type": "pathology",
  "@id": "vasc:rare:chemotherapy-toxicity",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:45:00.000Z",
    "updated": "2026-01-07T03:45:00.000Z",
    "contributors": ["vascular-surgery-agent"],
    "confidence": 0.85,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/rare-syndromes",
    "type": "iatrogenic-vascular-disease",
    "difficulty": "advanced",
    "importance": "medium"
  },
  "content": {
    "title": "Chemotherapy-Induced Vascular Toxicity",
    "description": "Vascular complications from chemotherapeutic agents including arterial thrombosis and Raynaud phenomenon.",
    "implicated_agents": {
      "platinum_compounds": "Cisplatin - arterial thrombosis, vasospasm",
      "vegf_inhibitors": "Bevacizumab - arterial thrombosis, hypertension, impaired wound healing",
      "vinca_alkaloids": "Vincristine/vinblastine - Raynaud phenomenon"
    },
    "clinical_manifestations": {
      "arterial_thrombosis": "Can occur during or after treatment",
      "raynaud": "Digital ischemia, may be severe",
      "hypertension": "VEGF inhibitor-associated"
    },
    "management": {
      "prevention": "Risk assessment before starting high-risk agents",
      "treatment": "Standard for arterial thrombosis; calcium channel blockers for Raynaud"
    },
    "clinical_pearl": "Consider chemotherapy history in unexplained arterial thrombosis in cancer patient without traditional risk factors"
  },
  "relationships": {
    "related_concepts": ["vasc:digital-ischemia", "vasc:raynaud"]
  },
  "provenance": {
    "primary_sources": [{"type": "textbook", "title": "Standard vascular surgery reference", "year": 2023}],
    "validation_status": "peer-reviewed"
  }
}
